H
Hakim-Moulay Dehbi
Researcher at University College London
Publications - 49
Citations - 2577
Hakim-Moulay Dehbi is an academic researcher from University College London. The author has contributed to research in topics: Medicine & Internal medicine. The author has an hindex of 16, co-authored 37 publications receiving 1860 citations. Previous affiliations of Hakim-Moulay Dehbi include Cancer Research UK & National Institutes of Health.
Papers
More filters
Journal ArticleDOI
Percutaneous coronary intervention in stable angina (ORBITA): a double-blind, randomised controlled trial.
Rasha Al-Lamee,Rasha Al-Lamee,David Thompson,David Thompson,Hakim-Moulay Dehbi,Sayan Sen,Sayan Sen,Kare Tang,John R. Davies,Thomas R. Keeble,Michael Mielewczik,Raffi Kaprielian,Iqbal S. Malik,Sukhjinder Nijjer,Ricardo Petraco,Ricardo Petraco,Christopher Cook,Christopher Cook,Yousif Ahmad,Yousif Ahmad,James P. Howard,James P. Howard,Christopher S. Baker,Andrew Sharp,Robert Gerber,Suneel Talwar,Ravi Assomull,Jamil Mayet,Jamil Mayet,Roland Wensel,David Collier,Matthew J. Shun-Shin,Matthew J. Shun-Shin,Simon Thom,Simon Thom,Justin E. Davies,Justin E. Davies,Darrel P. Francis,Darrel P. Francis,Amarjit Sethi,Punit Ramrakha,Rodney A. Foale,Ramzi Khamis,Nearchos Hadjiloizou,Masood Khan,Jaspal S. Kooner,Michael Bellamy,Ghada W. Mikhail,Piers Clifford,Peter O'Kane,Terry Levy,Rosie Swallow +51 more
TL;DR: In patients with medically treated angina and severe coronary stenosis, PCI did not increase exercise time by more than the effect of a placebo procedure, and the primary endpoint was difference in exercise time increment between groups.
Journal ArticleDOI
Use of the Instantaneous Wave-free Ratio or Fractional Flow Reserve in PCI
Justin E. Davies,Sayan Sen,Hakim-Moulay Dehbi,Hakim-Moulay Dehbi,Hakim-Moulay Dehbi,Rasha Al-Lamee,Ricardo Petraco,Sukhjinder Nijjer,Ravinay Bhindi,Sam J. Lehman,Darren L. Walters,James Sapontis,Luc Janssens,Christiaan J. Vrints,Ahmed Khashaba,Mika Laine,E. Van Belle,Florian Krackhardt,Waldemar Bojara,Olaf Going,Tobias Härle,Ciro Indolfi,Giampaolo Niccoli,Flavo Ribichini,Nobuhiro Tanaka,Hiroyoshi Yokoi,Hiroaki Takashima,Yuetsu Kikuta,Andrejs Erglis,Hugo Vinhas,P. Canas Silva,Sérgio Bravo Baptista,Ali Alghamdi,Farrel Hellig,Bon Kwon Koo,Chang Wook Nam,Eun-Seok Shin,Joon Hyung Doh,Salvatore Brugaletta,Eduardo Alegría-Barrero,Martijn Meuwissen,Jan J. Piek,N. van Royen,Murat Sezer,C. Di Mario,Robert Gerber,Iqbal S. Malik,Andrew S.P. Sharp,Suneel Talwar,Kare Tang,Habib Samady,John D. Altman,Arnold H. Seto,J. Singh,Allen Jeremias,Hitoshi Matsuo,Rajesh K. Kharbanda,Manesh R. Patel,P. Serruys,Javier Escaned,Javier Escaned +60 more
TL;DR: Coronary revascularization guided by iFR was noninferior to revascularizations guided by FFR with respect to the risk of major adverse cardiac events at 1 year.
Journal ArticleDOI
Discrepancies in Autologous Bone Marrow Stem Cell Trials and Enhancement of Ejection Fraction (DAMASCENE): Weighted Regression and Meta-Analysis
Alexandra N. Nowbar,Michael Mielewczik,Maria Karavassilis,Hakim-Moulay Dehbi,Matthew J. Shun-Shin,Siana Jones,James P. Howard,Graham D. Cole,Darrel P. Francis +8 more
TL;DR: Avoiding discrepancies is difficult but is important because discrepancy count is related to effect size, and in the five trials without discrepancies the effect of bone marrow stem cell therapy on ejection fraction is zero.
Journal ArticleDOI
Safety of the Deferral of Coronary Revascularization on the Basis of Instantaneous Wave-Free Ratio and Fractional Flow Reserve Measurements in Stable Coronary Artery Disease and Acute Coronary Syndromes.
Javier Escaned,Nicola Ryan,Hernán Mejía-Rentería,Christopher Cook,Hakim-Moulay Dehbi,Eduardo Alegría-Barrero,Ali Alghamdi,Rasha Al-Lamee,John D. Altman,Alphonse Ambrosia,Sérgio Bravo Baptista,Maria Bertilsson,Ravinay Bhindi,Mats Birgander,Waldemar Bojara,Salvatore Brugaletta,Christopher E. Buller,Fredrik Calais,Pedro Canas da Silva,Jörg Carlsson,Evald Høj Christiansen,Mikael Danielewicz,Carlo Di Mario,Joon Hyung Doh,Andrejs Erglis,David Erlinge,Robert Gerber,Olaf Going,Ingibjorg J. Gudmundsdottir,Tobias Härle,Dario Hauer,Farrel Hellig,Ciro Indolfi,Lars Jakobsen,Luc Janssens,Jens Jensen,Allen Jeremias,Amra Kåregren,Ann Charlotte Karlsson,Rajesh K. Kharbanda,Ahmed Khashaba,Yuetsu Kikuta,Florian Krackhardt,Bon Kwon Koo,Sasha Koul,Mika Laine,Sam J. Lehman,Pontus Lindroos,Iqbal S. Malik,Michael Maeng,Hitoshi Matsuo,Martijn Meuwissen,Chang-Wook Nam,Giampaolo Niccoli,Sukhjinder Nijjer,Hans Olsson,Sven Erik Olsson,Elmir Omerovic,Georgios Panayi,Ricardo Petraco,Jan J. Piek,Flavo Ribichini,Habib Samady,Bruce Samuels,Lennart Sandhall,James Sapontis,Sayan Sen,Arnold H. Seto,Murat Sezer,Andrew S.P. Sharp,Eun-Seok Shin,Jasvindar Singh,Hiroaki Takashima,Suneel Talwar,Nobuhiro Tanaka,Kare Tang,Eric Van Belle,Niels van Royen,Christoph Varenhorst,Hugo Vinhas,Christiaan J. Vrints,Darren L. Walters,Hiroyoshi Yokoi,Ole Fröbert,Manesh R. Patel,Patrick W. Serruys,Justin E. Davies,Justin E. Davies,Matthias Götberg +88 more
TL;DR: Overall, deferral of revascularization is equally safe with both iFR and FFR, with a low MACE rate of about 4%.
Journal ArticleDOI
Quarter-dose quadruple combination therapy for initial treatment of hypertension: placebo-controlled, crossover, randomised trial and systematic review
Clara K Chow,Clara K Chow,Clara K Chow,Jay Thakkar,Jay Thakkar,Alexander I. Bennett,Graham S. Hillis,Graham S. Hillis,Michael Burke,Tim Usherwood,Kha Vo,Kris Rogers,Emily Atkins,Ruth Webster,Michael Chou,Hakim-Moulay Dehbi,Abdul Salam,Anushka Patel,Anushka Patel,Bruce Neal,David Peiris,Henry Krum,John Chalmers,Mark Nelson,Christopher M. Reid,Mark Woodward,Sarah N. Hilmer,Simon Thom,Anthony Rodgers,Anthony Rodgers +29 more
TL;DR: The findings of this small trial in the context of previous randomised evidence suggest that the benefits of quarter-dose therapy could be additive across classes and might confer a clinically important reduction in blood pressure.